×
Volver a Agenda
[Session 6] Strategies to Assess, Prevent and Mitigate Cardiotoxicity
Session Chair(s)
Yuji Kumagai, MD, PHD
Professor, Kitasato Clinical Research Center, Kitasato University Hospital, Japan
Boaz Mendzelevski, MD
Consultant Cardiologist, Cardiac Safety Consultants Ltd., United Kingdom
Speaker(s)
Cardiovascular Safety Assessments of Oncology Drugs in Clinical Development
Consultant Cardiologist, Cardiac Safety Consultants Ltd., United Kingdom
Important Adverse Effects of Molecular-Targeting Drugs in Aspects of Cardio-Oncology
Institute for Advancement of Clinical and Translational Science (iACT) , Kyoto University Hospital, Japan
TKI Induced Cardiotoxicity and Drug-Induced Thrombosis
Deputy Manager, Department of Cardiovascular Medicine, Onco-Cardiology Unit, Osaka International Cancer Institute, Japan
Oncology Drug-Induced Cardiotoxicity: Strategies to Assess, Prevent and Mitigate Cardiotoxicity Pre- and Post-Approval
Deputy Director, Innovative Medicines, HQA/Licensing, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Cardio-Oncology from the Regulator’s Perspective
Reviewer, Office of New Drug V, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
¿Tiene una cuenta?